doi:10.1056/NEJMoa1411892 European Medicines Agency, 2025: non-arteritic anterior ischaemic optic neuropathy (NAION) added to semaglutide product information as a very rare adverse effect
There are certain peptides that hold promise for very narrow uses in clinical settings
While technology can support recovery and performance, the foundation of health will always come back to the basics: sleep, movement, hydration, nutrition, and sunlight
Increased Sensitivity: The degradation of ingredients can lead to increased skin sensitivity
this compound remains investigational
By slowing digestion, increasing feelings of fullness, and prompting the body to release more insulin, semaglutide helps patients eat less, control cravings, and lose weight safely and effectively